Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia
Research Article
Secretory IgA and Course of COVID-19 in Patients Receiving a Bacteria- Based Immunostimulant Agent in Addition to Background Therapy
Author(s): Michail Kostinov*, Oksana Svitich, Alexander Chuchalin, Valerij Osipcov, Ekaterina Khromova, Natal’ya Abramova, Vitalij Tatevosov, Anna Vlasenko, Viliya Gajnitdinova, Dmitry Pakhomov, Kirill Mashilov, Tat’yana Ospel’nikova, Natal’ya Mikhailova, Valentina Polishchuk, Ekaterina Kurbatova and Aristitsa Kostinova
Background: Mucosal immunity plays a major role not only in the prevention but probably also in the outcome of COVID-19. An enhanced production of secretory Immunoglobulin A (sIgA) might contribute to the activation of the immune response mechanisms.
Objective: To assess the levels of sIgA produced by epithelial cells in the nasal and pharyngeal mucosa and those measured in salivary gland secretions and to study the course of COVID-19 following the intranasal or subcutaneous administration of a bacteria-based immuno-stimulant agent.
Materials and methods: This study included 69 patients aged between 18 and 60, who had moderate COVID-19 infection. They were divided into two groups: Group 1 (control group) included 39 patients who received only background therapy, and Group 2 was made up of 30 patients who received b.. View More»
DOI:
10.35248/2155-9899.23.14.682